Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.72 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.49 |
| ▸ | TACR2 | P21452 | 3/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655204 | 0.93 | PTGER4 (0.62) | PTGER4SIRT2SIRT1SIRT3TACR2 | |
| SCHEMBL5654741 | 0.88 | PTGER4 (0.56) | PTGER4FOLH1CPB1CPB2 | |
| SCHEMBL5652220 | 0.86 | PTGER4 (0.55) | PTGER4FOLH1HTTSIRT5 | |
| SCHEMBL5653835 | 0.86 | PTGER4 (0.54) | PTGER4TACR2CPB1CPB2 | |
| SCHEMBL5654840 | 0.84 | PTGER4 (0.52) | PTGER4TACR2CPB1CPB2 | |
| SCHEMBL5653172 | 0.84 | PTGER4 (1.00) | PTGER4FOLH1HTTSIRT2SIRT1 | |
| SCHEMBL5651834 | 0.84 | PTGER4 (1.00) | PTGER4FOLH1HTTSIRT2SIRT1 | |
| SCHEMBL5653457 | 0.84 | PTGER4 (0.73) | PTGER4FOLH1HTTSIRT2SIRT1 | |
| SCHEMBL5657140 | 0.83 | PTGER4 (0.73) | PTGER4FOLH1HTTSIRT2SIRT1 | |
| SCHEMBL27656055 | 0.83 | PTGER4 (0.73) | PTGER4FOLH1HTTSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1697337-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN-E2-AGONISTS OR ANTAGONISTS | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061475-A2 | ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | PTGER4 1/4885FOLH1 2951/4885HTT 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.